Cabaletta Bio, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

CABA$1.45-3.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

	Common Stock
	Shares	Amount	AdditionalPaid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	TotalStockholders’ Equity
Balance—December 31, 2024	50,743,101	$1	$501,435	$—	$(349,101)	$152,335
Stock-based compensation	—	—	5,161	—	—	5,161
Net loss	—	—	—	—	(35,943)	(35,943)
Balance—March 31, 2025	50,743,101	$1	$506,596	$—	$(385,044)	$121,553
Issuance of common stock, warrants and pre-funded warrants, net of issuance costs of $6,442	39,200,000	—	93,558	—	—	93,558
Issuance of common stock from ATM offering, net of sales agent commission and fees	1,384,865	—	2,595	—	—	2,595
Issuance of common stock under employee stock purchase plan	123,933	—	197	—	—	197
Stock-based compensation	—	—	5,705	—	—	5,705
Net unrealized gains on available-for-sale securities	—	—	—	1	—	1
Net loss	—	—	—	—	(45,128)	(45,128)
Balance—June 30, 2025	91,451,899	$1	$608,651	$1	$(430,172)	$178,481
Stock-based compensation	—	—	5,815	—	—	5,815
Issuance of common stock in connection with exercise of stock options	13,334	—	14	—	—	14
Issuance of common stock upon exercise of pre-funded warrants	4,799,971	—	—	—	—	—
Net unrealized gains on available-for-sale securities	—	—	—	22	—	22
Net loss	—	—	—	—	(44,866)	(44,866)
Balance—September 30, 2025	96,265,204	$1	$614,480	$23	$(475,038)	$139,466

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

	Common Stock
	Shares	Amount	AdditionalPaid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	TotalStockholders’ Equity
Balance—December 31, 2025	100,479,323	$1	$628,982	$25	$(516,957)	$112,051
Issuance of common stock from ATM offering, net of sales agent commission and fees	8,055,260	—	22,568	—	—	22,568
Issuance of common stock upon exercise of common stock warrants	2,775,100	—	6,938	—	—	6,938
Issuance of common stock in connection with exercise of stock options	15,113	—	32	—	—	32
Stock-based compensation	—	—	5,256	—	—	5,256
Net unrealized losses on available-for-sale securities	—	—	—	(25)	—	(25)
Net loss	—	—	—	—	(43,515)	(43,515)
Balance—March 31, 2026	111,324,796	$1	$663,776	$—	$(560,472)	$103,305
Issuance of common stock, net of issuance costs of $9,801	51,725,000	—	140,201	—	—	140,201
Issuance of common stock from ATM offering, net of sales agent commission and fees	2,077,107	—	6,162	—	—	6,162
Issuance of common stock upon exercise of common stock warrants	2,500,000	—	6,250	—	—	6,250
Issuance of common stock in connection with exercise of stock options	19,144	—	34	—	—	34
Issuance of common stock under employee stock purchase plan	80,490	—	160	—	—	160
Stock-based compensation	—	—	5,499	—	—	5,499
Net loss	—	—	—	—	(51,018)	(51,018)
Balance—June 30, 2026	167,726,537	$1	$822,082	$—	$(611,490)	$210,593
Issuance of common stock from ATM offering, net of sales agent commission and fees	1,924,835	—	5,984	—	—	5,984
Issuance of common stock upon exercise of common stock warrants	46,011,900	1	115,029	—	—	115,030
Issuance of common stock in connection with exercise of stock options	57,120	—	101	—	—	101
Stock-based compensation	—	—	5,264	—	—	5,264
Net loss	—	—	—	—	(53,053)	(53,053)
Balance—September 30, 2026	215,720,392	$2	$948,460	$—	$(664,543)	$283,919

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.